Drug Trial Radar · NCT05864014
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.
Last checked: Nov 19, 2026Latest source record: Apr 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
213
Actual
Start
Apr 25, 2023
Primary completion
Mar 3, 2025
Study completion Sep 2025
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of current study is to evaluate the efficacy and safety of hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors.
Conditions
- Chemotherapy-Induced Thrombocytopenia
Interventions
HetrombopagDrug
Hetrombopag
Hetrombopag plus PlaceboDrug
Hetrombopag plus Placebo
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of treatment responders.Time frame: Randomization up to 80 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hematology Tumor Research Center of Harbin First Hospital
Haerbin, Heilongjiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.